N/A N=58 Speech Therapy for Aphasia: Comparing Two Treatments
Stroke
Primary: Spoken Word Production (Confrontation Naming) — 53.01; 50.37 percent correct
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=556 Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
Primary Open Angle Glaucoma
Primary: Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout. — 77.2; 57.8 percentage of eyes
Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Phase 2 N=143 S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival — 5; 8 months — p=0.384
N/A N=45 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Myelodysplastic Syndrome · Effects of Chemotherapy · Mild Cognitive Impairment
Primary: Change From Baseline Capture Task Performance at 1- and 3- Months — .103; -.039; .066; .067 change in proportional response time
N/A N=38,514 Impact of Radiation Therapy on Breast Conservation in DCIS
DCIS
Primary: Association Between Patient Characteristics and Three-Level Cluster of Treatment Intensity for Primary DCIS — 145; 115; 99; 0 Participants — p=<0.05
Phase 2 N=33 Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
Malignant Neoplasm
Primary: Total Dose of Propofol Administered to Each Patient — 2.94; 3.22 mg/kg — p=0.036
Phase 3 N=313 Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in Total Nasal Symptom Score Averaged Over Day 1 Through Day 15 (Based on Participant Diaries) — -2.8; -3.4; -0.9 Score on a scale — p=<0.01
Phase 1 N=16 A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
Colitis, Ulcerative · Crohn Disease
Primary: Cmax: Maximum Observed Serum Concentration for Vedolizumab — 136.4120 microgram per milliliter (mcg/mL)
Phase 2 N=38 Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: 18 Week Progression-free Survival Rate — 35; 72 percentage of participants
Phase 3 N=12 LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
Hemophilia
Primary: Percentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality…
Phase 4 N=284 Uterotonic Prophylaxis Trial
Hemorrhage
Primary: Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria — 78; 75 Participants — p=0.5
Phase 4 N=53 An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face
Aged Skin
Primary: Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Subject — 91.7; 80.0; 79.2; 72.0 % improved participants
Phase 2 N=11 N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: OCD Severity at 12 Weeks — 21.4; 21.3 points on a scale
Phase 1 N=14 A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254
HIV Infections
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3640254 Following Single Oral Dose in Healthy…